Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...

The devastating statistics about deaths from colon cancer have put the spotlight on a dreaded disease, which, today, could be ...

Learn how stool appearance can signal colon cancer. Recognize signs like ribbon-like and pebble-shaped stools, and understand ...

Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics ...

During a colonoscopy, if a doctor finds any polyps — abnormal growths that can sometimes turn cancerous — they typically ...

Millions remain unscreened for colorectal cancer. Learn how noninvasive screening can expand access, preserve capacity, and ...

Rhythm Biosciences has materially improved the predictive accuracy of its geneType colorectal cancer risk assessment clinical ...

FIT checks for blood in the stool, which can indicate the presence of colorectal cancer or polyps. Patients collect stool ...

Dr Sood shares why colonoscopy prep can be an uncomfortable experience, but is absolutely necessary for the procedure to have the intended result.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for ...

Researchers investigated whether the time interval between a positive FIT result and follow-up colonoscopy is linked to risk for CRC.

Colonoscopy remains a cornerstone of colorectal cancer prevention, but GI leaders say the procedure’s role, and the business model built around it, is shifting fast. Here’s what five leaders have told ...